LYON, France–(BUSINESS WIRE)– MaaT Pharma (EURONEXT: MAAT – the “Firm”), a French clinical-stage biotech and a pioneer within the improvement of microbiome-based ecosystem therapies devoted to enhancing survival outcomes for sufferers with most cancers, introduced on March 28th, 2022, the inclusion of the primary affected person in a pivotal Section 3 scientific trial, doubtlessly the final step of scientific improvement earlier than advertising and marketing authorization, evaluating MaaT013 for the therapy of acute gastrointestinal Graft-versus-Host Illness (aGvHD), a severe complication following stem cell transplantation. Yearly, greater than 10,000 persons are identified in Europe and in the US of America1, and the prognosis for the sufferers with probably the most superior kind is poor with a mortality fee of as much as 80%2 within the first yr. This new milestone for MaaT Pharma, the primary Euronext-listed firm creating microbiome-based therapies, builds on the success story of its founding partnership with INRAE initiated in 2014, specifically through the scientific help settlement3 between MaaT Pharma, INRAE and Dr. Joël Doré, INRAE Analysis Director, Scientific Director of Métagénopolis, writer of practically 500 publications, and one of the world’s most cited authors within the microbiome sphere at present.
This press launch options multimedia. View the total launch right here: https://www.businesswire.com/news/home/20220420005889/en/
On the finish of 2014, following a venture improvement interval as an entrepreneur-in-residence with Seventure Companions, Hervé Affagard, presently CEO, based MaaT Pharma alongside Dr. Joël Doré, now MaaT Pharma’s Scientific Advisor. As early as 2015, MaaT Pharma and INRAE co-filed three patents, for which the Firm now holds unique exploitation rights. These patents are additionally on the root of the event of the Firm’s native merchandise, MaaT013 and MaaT033, each presently in scientific trials.
“Microbiome science has been on the coronary heart of my analysis for greater than 30 years. INRAE has established itself first as a pioneer, then as a global heart of excellence within the discipline. In 2021, for instance, INRAE was the 5th largest educational participant on the planet by way of microbiome-related patents. For my part, the speedy progress of MaaT Pharma, which has entered a Section 3 scientific trial, completely illustrates the environment friendly and profitable transition from pioneering science to modern therapeutic improvement for the advantage of sufferers. By my analysis, I hope to contribute to the quick emergence of a brand new medicinal modality, that takes into consideration the symbiotic relationship between human well being and the microbiome,” mentioned Dr. Doré.
Following the arrival of metagenomics4, the analysis produced at INRAE on the intestine microbiome has led to unprecedented outcomes disrupting our understanding of the digestive ecosystem, and opening novel avenues for enhancing the well being of tens of millions of sufferers worldwide affected by cancers, metabolic illnesses, or inflammatory illnesses to call only a few of the potential indications.
MaaT Pharma has developed a portfolio of three merchandise since its creation together with two presently in scientific phases. The Firm has initiated 5 Section 1 and Section 2 scientific trials, consolidated its patent portfolio (together with 13 worldwide patent households), and raised a complete of €83 million. The Firm presently employs 45 folks and MaaT013 has been administered to greater than 100 folks with aGvHD in a Section 2 scientific trial and in an ongoing compassionate entry program5 in France.
Hervé Affagard, CEO and co-founder of MaaT Pharma commented, “Since our basis, we now have been trying to develop the microbiome ecosystem in France and have solid partnerships with medical and scientific facilities of excellence in addition to with famend industrial gamers to develop the Firm. In 2016, we launched our first scientific trial simply 18 months after the corporate’s creation, and we now have since strengthened our place as a pioneer in microbiome-based therapies in oncology. Our translational experience permits us to quickly remodel science into groundbreaking and secure drug candidates, with the help of our scientific companions, to enhance survival consequence for most cancers sufferers.”
The collaboration between these two pioneers continues to maneuver ahead with the formation of business constructions and the expansion of nationwide experience within the microbiome house in Europe with the Alliance Promotion Microbiote (APM), of which each organizations are among the many co-founders. APM is an affiliation below the French regulation of 1901 and contains 25 non-public and public gamers (corporations, clusters, analysis institutes, funding funds), of which Hervé Affagard was elected president in January 2022. APM goals to contribute to creating France, a pioneering nation in microbiome analysis and engineering, right into a European chief to fulfill the present and future challenges of this sector acknowledged in 2021 as a precedence within the “Well being Innovation Plan 2030 “.
Created on January 1, 2020, the French Nationwide Analysis Institute for Agriculture, Meals, and Atmosphere (INRAE) is a significant participant in analysis and innovation. INRAE carries out focused analysis and resulted from the merger of INRA and IRSTEA. It’s a neighborhood of 12,000 folks with 273 analysis, experimental analysis, and help items situated in 18 regional centres all through France. Internationally, INRAE is among the many prime analysis organisations within the agricultural and meals sciences, plant and animal sciences, in addition to in ecology and environmental science. It’s the world’s main analysis organisation specialising in agriculture, meals and the surroundings. INRAE’s objective is to be a key participant within the transitions mandatory to handle main world challenges. Confronted with a rising world inhabitants, local weather change, useful resource shortage, and declining biodiversity, the institute is creating options that contain multiperformance agriculture, high-quality meals, and the sustainable administration of assets and ecosystems.
About MaaT Pharma
MaaT Pharma, a scientific stage biotechnology firm, has established a whole method to restoring patient-microbiome symbiosis in oncology. Dedicated to treating most cancers and graft-versus-host illness (GvHD), a severe complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, a Section 3 scientific trial for sufferers with acute GvHD, following the achievement of its proof of idea in a Section 2 trial. Its highly effective discovery and evaluation platform, gutPrint®, helps the event and growth of its pipeline by figuring out novel illness targets, evaluating drug candidates, and figuring out biomarkers for microbiome-related circumstances.
The corporate’s Microbiome Ecosystem Therapies are produced by a standardized cGMP manufacturing and high quality management course of to soundly ship the total range of the microbiome, in liquid and oral formulations. MaaT Pharma advantages from the dedication of world-leading scientists and established relationships with regulators to help the combination of the usage of microbiome therapies in scientific follow.
MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
All statements apart from statements of historic reality included on this press launch about future occasions are topic to (i) change with out discover and (ii) elements past the Firm’s management. These statements might embody, with out limitation, any statements preceded by, adopted by or together with phrases corresponding to “goal,” “imagine,” “count on,” “goal,” “intend,” “might,” “anticipate,” “estimate,” “plan,” “venture,” “will,” “can have,” “possible,” “ought to,” “would,” “may” and different phrases and phrases of comparable which means or the adverse thereof. Ahead-looking statements are topic to inherent dangers and uncertainties past the Firm’s management that might trigger the Firm’s precise outcomes or efficiency to be materially completely different from the anticipated outcomes or efficiency expressed or implied by such forward-looking statements.
1 Supply: World Information GVHD Epidemiology Report, Jan 2020.
2 Supply: Essai REACH1
3 Article L 531-8 and 9 of the French Analysis Code permitting the participation of analysis personnel within the creation of corporations or within the actions of an organization and the promotion of their work
4 metagenomics: a way used to check the microbiome – Qin, J., Li, R., Raes, J. et al. A human intestine microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010)
5 Compassionate use packages permit the usage of investigational medicine earlier than they’re approved for advertising and marketing for sufferers with no treatment-options.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20220420005889/en/